SYMBRAVO
- Product NDC
- 81968-020
- 11-digit product format
- 819680020
- Labeler code
- 81968
- Product ID
- 81968-020_b625951b-f029-470d-8d35-f5b6a92a06bb
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- meloxicam, rizatriptan
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Axsome Therapeutics, Inc.
- Application
- NDA215431
- Marketing category
- NDA
- Marketing start
- 2025-05-19
- Substance
- MELOXICAM; RIZATRIPTAN BENZOATE
- Active strength
- 20; 10 mg/1; mg/1
- Pharmacologic classes
- Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC], Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N215431-001 | SYMBRAVO | MELOXICAM; RIZATRIPTAN BENZOATE | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N215431-001 | 10029010 | 2036-04-11 | U-4133 | 2025-02-27 | |
| N215431-001 | 10058614 | 2036-04-11 | Drug product | 2025-02-27 | |
| N215431-001 | 10137131 | 2036-04-11 | U-1719 | Drug product | 2025-02-27 |
| N215431-001 | 10195278 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10265324 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10265399 | 2036-04-11 | U-4509 | 2026-05-22 | |
| N215431-001 | 10265400 | 2036-04-11 | U-4509 | 2026-05-22 | |
| N215431-001 | 10307484 | 2036-04-11 | U-4509 | 2026-05-22 | |
| N215431-001 | 10363312 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10369224 | 2036-04-11 | U-4134 | 2025-02-27 | |
| N215431-001 | 10369225 | 2036-04-11 | U-4356 | 2026-05-22 | |
| N215431-001 | 10426839 | 2036-04-11 | U-4135 | 2025-02-27 | |
| N215431-001 | 10456471 | 2036-04-11 | U-4509 | 2026-05-22 | |
| N215431-001 | 10463736 | 2036-04-11 | Drug product | 2025-02-27 | |
| N215431-001 | 10471014 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10471069 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10512692 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10512693 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10517950 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10532101 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10537642 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10561664 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10583144 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10653777 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10688102 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10688185 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10695429 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10695430 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10702535 | 2036-04-11 | U-4136 | 2025-02-27 | |
| N215431-001 | 10702602 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10722583 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10729696 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10729697 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10729773 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10758617 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10758618 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10780165 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10780166 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10799588 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10821181 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10821182 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10894053 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10905693 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10918722 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10933136 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10933137 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10940153 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 10987358 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11013805 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11013806 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11020483 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11045549 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11135295 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11207328 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11219626 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11266657 | 2036-04-11 | U-1719 | 2026-05-22 | |
| N215431-001 | 11285213 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11331323 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11369684 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11426414 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11433078 | 2036-04-11 | U-1719 | 2026-05-22 | |
| N215431-001 | 11433079 | 2036-04-11 | U-1719 | 2026-05-22 | |
| N215431-001 | 11471464 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11471465 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11504429 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11510927 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11571428 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11602563 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11607456 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11617755 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11617756 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11617791 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11628173 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11712441 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11738085 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11759522 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11801250 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11806354 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11826370 | 2036-04-11 | U-1719 | 2025-02-27 | |
| N215431-001 | 11865117 | 2036-04-11 | U-1719 | 2025-02-27 |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N215431-001 | NP | 2028-01-30 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | b8a1b40f171c… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N215431-001 | SYMBRAVO | 20MG;EQ 10MG BASE | TABLET / ORAL | RLD, RS | 2025-01-30 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10029010 | 2036-04-11 | U-4133 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10058614 | 2036-04-11 | Drug product | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10137131 | 2036-04-11 | U-1719 | Drug product | 2025-02-27 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10195278 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10265324 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10265399 | 2036-04-11 | U-4509 | 2026-05-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10265400 | 2036-04-11 | U-4509 | 2026-05-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10307484 | 2036-04-11 | U-4509 | 2026-05-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10363312 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10369224 | 2036-04-11 | U-4134 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10369225 | 2036-04-11 | U-4356 | 2026-05-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10426839 | 2036-04-11 | U-4135 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10456471 | 2036-04-11 | U-4509 | 2026-05-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10463736 | 2036-04-11 | Drug product | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10471014 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10471069 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10512692 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10512693 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10517950 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10532101 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10537642 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10561664 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10583144 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10653777 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10688102 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10688185 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10695429 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10695430 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10702535 | 2036-04-11 | U-4136 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10702602 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10722583 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10729696 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10729697 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10729773 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10758617 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10758618 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10780165 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10780166 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10799588 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | 10821181 | 2036-04-11 | U-1719 | 2025-02-27 | 84e616aacf4f… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215431-001 | NP | 2028-01-30 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N215431-001 | NP | 2028-01-30 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N215431-001 | NP | 2028-01-30 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215431-001 | NP | 2028-01-30 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N215431-001 | NP | 2028-01-30 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215431-001 | NP | 2028-01-30 | fd3edfee7708… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N215431-001 | NP | 2028-01-30 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- SYMBRAVO
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| MELOXICAM | 20 mg/1 |
| RIZATRIPTAN BENZOATE | 10 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| VG2QF83CGL | Internal UNII lookup |
| WR978S7QHH | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| bdef11ce-16e2-4690-96a3-597bcf5cc738 | Product name | 1 | 20260130 |
| f2791553-0b76-42f4-8d49-af3eda072bfb | Product name | 1 | 20251117 |
| 707ffe6e-db52-42b0-9a65-a0c00213f04f | Product name | 1 | 20231006 |
| e3a99641-4540-4894-9108-00cab3c57b7e | Product name | 1 | 20211207 |
| 3e9b4ed6-844c-4725-9d19-cceb5c823572 | Product name | 2 | 20210903 |
| b21a682e-c765-4e26-9bb2-dbb8c7b38ef7 | Product name | 1 | 20200623 |
| a428d1db-64d7-4fc3-8d13-832b1e84b683 | Product name | 1 | 20190201 |
| 8b537454-32b8-7e64-1395-258682782d07 | Product name | 5 | 20170424 |
| 96649a58-aac8-401c-be00-450b4335f7e7 | Product name | 1 | 20161116 |
| f0761cb7-8207-3a19-2ca3-ecbb559b04e1 | Product name | 2 | 20161116 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 81968-020-02 | SYMBRAVO | 1 in 1 CARTON | TABLET | 1 | 5 | |
| 81968-020-02 | SYMBRAVO | 2 in 1 BOTTLE | TABLET | 2 | 5 | |
| 81968-020-03 | SYMBRAVO | 3 in 1 BOTTLE | TABLET | 3 | 5 | |
| 81968-020-03 | SYMBRAVO | 1 in 1 CARTON | TABLET | 1 | 5 | |
| 81968-020-09 | SYMBRAVO | 9 in 1 BOTTLE | TABLET | 9 | 5 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 81968-020-09 | EA - Each | 81968-020 | f539d324-98bb-4e05-af0b-ec04970b98b1 | 1 | 2025-05-14 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SYMBRAVO | MELOXICAM, RIZATRIPTAN | Axsome Therapeutics, Inc. | dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | 2025-11-21 | Boxed warning, Warnings, Adverse reactions | 215431 NDA215431 81968-020 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 2711789 | meloxicam 20 MG / rizatriptan 10 MG Oral Tablet | PSN | dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | 5 |
| 2711795 | SYMBRAVO 20 MG / 10 MG Oral Tablet | PSN | dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | 5 |
| 2711795 | meloxicam 20 MG / rizatriptan 10 MG Oral Tablet [Symbravo] | SBD | dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | 5 |
| 2711789 | meloxicam 20 MG / rizatriptan 10 MG Oral Tablet | SCD | dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | 5 |
| 2711789 | meloxicam 20 MG / rizatriptan 10 MG (as rizatriptan benzoate 14.5 MG) Oral Tablet | SY | dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | 5 |
| 2711795 | Symbravo (meloxicam 20 MG / rizatriptan 10 MG) Oral Tablet | SY | dcf1ecd1-08a0-8e47-e053-2a95a90abdc7 | 5 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 81968-020-02 | 81968002002 | 1 BOTTLE in 1 CARTON (81968-020-02) / 2 TABLET in 1 BOTTLE | 1 bottle | 2025-11-21 | Yes | No | Current |
| 81968-020-03 | 81968002003 | 1 BOTTLE in 1 CARTON (81968-020-03) / 3 TABLET in 1 BOTTLE | 1 bottle | 2025-05-19 | Yes | No | Current |
| 81968-020-09 | 81968002009 | 9 TABLET in 1 BOTTLE (81968-020-09) | 9 tablet | 2025-05-19 | No | No | Current |